Related Experiment Video
Updated: May 19, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the
Ulrich Mrowietz1, Rachel Sommer2, Ziad Reguiai3
1Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Psoriasis (Auckland, N.Z.)
|May 18, 2026
Summary
Tildrakizumab significantly improved skin symptoms, psychological well-being, and quality of life in patients with moderate-to-severe psoriasis over two years. This interleukin-23p19 inhibitor demonstrated sustained efficacy and a favorable safety profile in real-world settings.
Area of Science:
- Dermatology
- Immunology
- Clinical Research
Background:
- Psoriasis impacts skin, psychological health, and daily functioning.
- Interleukin-23p19 inhibitors offer a targeted treatment approach.
Purpose of the Study:
- To evaluate the 2-year real-world effects of tildrakizumab on skin, psychological well-being, and quality of life in moderate-to-severe psoriasis patients.
Main Methods:
- The POSITIVE study was a 24-month prospective observational multinational trial.
- Adults with moderate-to-severe plaque psoriasis receiving tildrakizumab were enrolled.
- Outcome measures included WHO-5, PASI, and DLQI-R scores.
Main Results:
- Significant improvements in WHO-5 scores (psychological well-being) and reductions in PASI scores (skin severity) were observed over 2 years.
- Dermatology Life Quality Index-Relevant (DLQI-R) scores substantially decreased, indicating improved quality of life.
- High drug survival rates (87.8%) and a favorable safety profile with low adverse event incidence (11.1%) were noted.
Conclusions:
- Tildrakizumab provides sustained, holistic long-term health benefits for moderate-to-severe psoriasis.
- The treatment consistently improved psychological well-being, clinical outcomes, and quality of life.
- Tildrakizumab demonstrated a favorable safety profile over the 2-year study period.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...